Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Nyxoah S.A.NASDAQ: NYXH

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of €7.36M rose 591.9% year over year, ahead of the +273.9% change in trailing-twelve-month revenue. Sequentially, it rose 30.4% from the prior quarter. Over 3 fiscal years it compounded at +48.1% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of €37.32M (+272.5%) for the fiscal year ending Dec 2026, a step up from the +121.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
€7.36M+30.4% QoQ
Last fiscal yearDec 2025
€10.02M+121.6% YoY
LTMMar 2026
€16.32M+273.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+591.9%+544.5%-47.4 pp
1 year+121.6%+272.5%+150.8 pp
3-year CAGR+48.1%+124.3%+76.2 pp
5-year CAGR+93.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

EUR · from the income statement

Latest · FY2025
10.02M EUR
Year-over-year change
+121.6%
4-year CAGR
+85.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How NYXH compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +273.9% is the highest of 9, against a peer median of +15.7%.
  • Over three fiscal years its annual growth of +48.1% compares with a peer median of -9.7%.
NYXH Competitors
Revenue for NYXH and competitors
Company Period LTM YoY 3-year CAGR
STIMNeuronetics, Inc.LTM Mar 2026$151.64M USD+69.5%+31.8%
PREPrenetics Global LimitedLTM Mar 2026$113.75M USD+174.0%+91.5%
OSUROraSure Technologies, Inc.LTM Mar 2026$113.02M USD-30.1%-33.3%
IVVDInvivyd, Inc.LTM Mar 2026$55.87M USD+52.3%—
KRMDKORU Medical Systems, Inc.LTM Mar 2026$43.26M USD+23.3%+13.8%
UTMDUtah Medical Products, Inc.LTM Mar 2026$37.53M USD-4.4%-9.7%
OABIOmniAb, Inc.LTM Mar 2026$28.91M USD+8.1%-31.9%
NYXHNyxoah S.A.LTM Mar 2026€16.32M EUR+273.9%+48.1%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$618K USD-58.0%-50.1%
TARAProtara Therapeutics, Inc.LTM Mar 2026$0 USD——
Peer median (excluding NYXH) —+15.7%-9.7%

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue852K3.08M4.35M4.52M10.02M
Cost of Revenue303K1.15M1.66M1.55M3.69M
Gross Profit549K1.93M2.69M2.97M6.33M
Gross Margin64.4%62.7%61.9%65.7%63.1%
Research & Development5.95M15.86M27.66M34.33M42.82M
Selling, General & Admin11.11M18.86M20.65M28.46M46.44M
Operating Expenses26.79M34.43M47.79M61.78M89.27M
Depreciation & Amortization1.66M1.93M2.36M764K4.48M
EBITDA(22.59M)(27.89M)(42.08M)(53.77M)(82.9M)
EBITDA Margin-2651.5%-904.2%-967.8%-1189.2%-827.4%
Operating Income(26.24M)(32.5M)(45.1M)(58.81M)(82.94M)
Operating Margin-3080.0%-1053.8%-1037.3%-1300.8%-827.8%
Interest Income1K372K2.57M2.5M1.83M
Interest Expense386K237K1.21M1.9M1.69M
Other Income / Expenses1.6M2.44M445K2.38M(6.13M)
Income Before Tax(24.64M)(30.06M)(44.66M)(56.43M)(89.08M)
Pre-Tax Margin-2891.9%-974.6%-1027.1%-1248.2%-889.0%
Income Tax Expense2.98M1.17M(1.45M)2.8M1.01M
Net Income(27.62M)(31.23M)(43.21M)(59.24M)(90.09M)
Net Margin-3241.7%-1012.5%-993.8%-1310.2%-899.1%
EPS (Basic)(1.16)(1.21)(1.55)(1.81)(2.37)
EPS (Diluted)(1.16)(1.21)(1.55)(1.81)(2.37)
Weighted Avg Shares23.79M25.82M27.97M32.74M38.11M
Weighted Avg Shares (Diluted)23.79M25.82M27.97M32.74M38.11M

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.